Research
Hormonal
n-3 omega fatty acids reduce inflammation by inhibiting the production of pro-inflammatory eicosanoids (PGE2, TXA2, LTB4) and promoting anti-inflammatory eicosanoids (PGE1, PGI3, LTB5).
Incorporating n-3 omega fatty acids into your diet helps reduce systemic inflammation by shifting your body's production of inflammatory mediators towards anti-inflammatory ones. This is beneficial for conditions like rheumatoid arthritis and inflammatory bowel disease.
StrongSupportsVERY_HIGH confidence
In contrast, emulsions rich in EPA, LN and DHA (n-3 omega PUFAs) inhibit the breakdown of AA, which is produced by the synthesis of PGE2... This group (LN and dihomo a-LN) produces PGE1... PGE3 and PGI3 have got beneficial effects similar to those of PGE1, such as inhibiting inflammation
Why this rating
The biochemical pathway is well-established and cited extensively in the paper.
Source
n‐3 Omega fatty acids: a review of current knowledge
Uğur Göğüş et al. · International Journal of Food Science & Technology · 2010
DOI 10.1111/j.1365-2621.2009.02151.x
narrative_reviewCited 358×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Daily intake of 1-3 grams of n-3 omega fatty acids (EPA/DHA) reduces cardiovascular risk by lowering serum triglycerides and LDL cholesterol, and inhibiting platelet aggregation.Good
- High doses of n-3 omega fatty acids (1.8 g/day) may accelerate heart rate and increase the risk of ventricular tachycardia or fibrillation in patients with existing ventricular arrhythmias.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →